"Ticlopidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
| Descriptor ID |
D013988
|
| MeSH Number(s) |
D02.886.778.823.500 D03.383.725.849.500 D03.383.903.830.500 D03.633.100.928.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ticlopidine".
Below are MeSH descriptors whose meaning is more specific than "Ticlopidine".
This graph shows the total number of publications written about "Ticlopidine" by people in this website by year, and whether "Ticlopidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 5 | 0 | 5 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 4 | 6 |
| 2008 | 3 | 5 | 8 |
| 2009 | 5 | 4 | 9 |
| 2010 | 6 | 0 | 6 |
| 2011 | 8 | 2 | 10 |
| 2012 | 5 | 2 | 7 |
| 2013 | 9 | 4 | 13 |
| 2014 | 5 | 2 | 7 |
| 2015 | 2 | 3 | 5 |
| 2016 | 7 | 0 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ticlopidine" by people in Profiles.
-
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions. Cancer Treat Res. 2022; 184:75-85.
-
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
-
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Int J Cardiol. 2018 Jan 01; 250:49-55.
-
Response by Lee and Ovbiagele to Letter Regarding Article, "Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis". Stroke. 2017 10; 48(10):e312.
-
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
-
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. Stroke. 2017 09; 48(9):2610-2613.
-
Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. J Am Coll Cardiol. 2017 04 25; 69(16):2023-2025.
-
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.
-
Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
-
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).